IP Library Granted Patent US 8,784,776
Granted Patent B2
US 8,784,776 · App. 12/866,519 · Granted Jul 22, 2014

Use of FSH receptor ligands for diagnosis and therapy of cancer

Inventors: Nicolae Ghinea (Creteil, FR); Aurelian Radu (New York, NY)
Assignees: Inserm (Institut National de la Sante et de la Recherche Medicale); Mount Sinai School of Medicine
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,784,776
App. No.
12/866,519
Granted
Jul 22, 2014
Kind
B2
Abstract

The present invention relates to diagnostic imaging and in particular to the diagnostic imaging and therapy of cancer by means of compositions which specifically target the FSH Receptor expressed by tumor endothelial cells and circulating blood cells.

Claims (13)

1. A method for imaging vessels associated with a tumor in a patient, the method comprising administering a labeled Vascular Endothelial follicle-stimulating hormone (FSH) receptor (VE-FSHR) ligand to said patient and imaging said patient to detect the in vivo binding of said ligand to a VE-FSHR in vessels associated with the tumor in said patient.

2. The method according to claim 1 , wherein the FSH receptor (FSHR) ligand is a detectably labeled anti-FSHR antibody.

3. The method according to claim 1 , wherein the FSH receptor (FSHR) ligand is detectably labeled FSH.

4. The method according to claim 1 , wherein said tumor is selected from the group consisting of prostate, kidney, ovary, testis, lung, liver, pancreas, stomach, breast, colon, brain and urinary bladder cancer.

5. The method according to claim 4 , wherein the prostate cancer is prostate adenocarcinoma.

6. The method according to claim 1 , wherein the FSH receptor (FSHR) ligand localizes or determines the size of the tumor in vivo.

7. The method according to claim 1 , wherein said method evaluates the severity of a cancer or monitors the efficacy of an anti-tumor therapy.

8. The method according to claim 1 , wherein the FSH receptor (FSHR) ligand is administered intravenously.

9. The method according to claim 1 , wherein said FSH receptor (FHSR) ligand is labeled with a gas-filled microvesicle.

10. The method according to claim 1 , wherein said method comprises contrast enhanced ultrasound imaging.

11. The method according to claim 1 , wherein the tumor is a primary tumor or a metastatic lesion.

12. The method according to claim 1 , wherein said vessels are blood vessels associated with the tumor.

13. The method according to claim 1 , wherein said vessels are microvessels associated with the tumor.

Assignments (3)
CHANGE OF NAME Recorded Jun 10, 2015
From: MOUNT SINAI SCHOOL OF MEDICINE
To: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Reel/Frame 035874/0140 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2011
From: RADU, AURELIAN
To: MOUNT SINAI SCHOOL OF MEDICINE
Reel/Frame 027205/0666 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2011
From: GHINEA, NICOLAE
To: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Reel/Frame 027205/0695 →
Priority Claims (1)
EP 08305026 · Feb 18, 2008 · regional
Continuity (1)
Related Publication 20100316572A1 · Dec 16, 2010